OraSure Technologies Inc. 2026 Third Quarter Earnings Conference Call - ORASURE TECHNOLOGIES INC

Financial Performance:

• Q3 2026 total revenue reached $30.9 million, marking a 14% year-over-year increase and 1% sequential growth.
• Diagnostic products revenue grew 16% YoY to $16.8 million, driven by international HIV, U.S. HCV, and Sickle Scan; Sample Management Solutions (SMS) grew 21% YoY to $12.5 million.
• Gross margin expanded 173 basis points to 45.2% (GAAP) and 45.0% (Non-GAAP), attributed to operational efficiencies and overhead absorption.
• Operating expenses declined significantly: R&D dropped $1.8 million sequentially to $7.6 million; G&A fell $2.4 million to $12.0 million due to reduced non-recurring legal costs; S&M remained flat at $6.6 million.
• Adjusted operating loss narrowed to $13.0 million (up from prior year context) and non-GAAP operating loss to $10.2 million; operating cash flow was negative $10.9 million.
• Balance sheet remained strong with zero debt and $148.2 million in cash and cash equivalents.

Guidance and Future Outlook:

• Q4 2026 revenue guidance is set between $30.0 million and $32.0 million, implying 12–20% YoY growth; full-year 2026 revenue is projected between $119.5 million and $121.5 million (3.8–5.6% growth).
• Cash flow from operations (OCF) break-even target has been revised from early 2027 to the second half of 2027, reflecting timing changes in growth opportunities following the CTNG withdrawal.
• Full-year 2027 revenue growth is expected to accelerate compared to 2026, driven by portfolio expansion and new product launches.
• Q4 gross margins are expected to remain similar to or slightly below Q3 levels, with long-term margin improvement driven by manufacturing scale.
• Management anticipates providing more detailed 2027 growth insights, including the impact of Colipi DX and Ebola testing, during the Q4 earnings call.

Business Segments and Product Lines:

• International Diagnostics: Stabilized HIV performance in African markets; launched local assembly in Uganda with plans for Nigeria; driving growth via Sickle Scan and early Ebola adoption.
• U.S. Diagnostics: Growth driven by syndemic testing (HIV, HCV, Syphilis) and strengthened funding dynamics; FDA pre-submission process ongoing for IntelliQuick CT and G Test on the Sherlock platform.
• Sample Management Solutions: Launched FDA-cleared Colipi DX Urine Collection Kit in Q3; initial commercial orders received with strong interest from customers evaluating self-collected workflows.
• Strategic Investments: OTI retains a minority stake in Onvera (formerly Safros) following Safros' merger with Banks Health; strategic agreements with Safros remain active.

Market and Competitive Landscape:

• Ebola Outbreak: WHO reports >10,600 confirmed cases and nearly 5,200 deaths in DRC and neighboring regions; OTI holds FDA EUA for OraQuick Ebola 2.0, which detects all four known Ebola species.
• Local Manufacturing Trend: Shift toward African-led health security and self-reliance is accelerating demand for localized testing infrastructure, aligning with OTI's Uganda assembly launch.
• Public Health Partnerships: Active engagement with Africa CDC, WHO, UNITAID, and the World Coalition on Sickle Cell Disease to validate diagnostics and expand access; Bridge Access Platform Study results anticipated to drive regional registration and procurement.
• STI Market: Colipi DX addresses unmet need for convenient, private urine sample collection to expand STI testing access.

Risks and Challenges:

• Regulatory Delays: CTNG molecular self-test resubmission timeline remains uncertain; dependent on FDA pre-submission outcomes and potential additional clinical trials.
• Market Access Friction: Evolving African registration and procurement processes, while creating long-term self-reliance, are currently lengthening adoption timelines compared to immediate outbreak needs.
• Order Timing: Revenue mix fluctuates quarter-over-quarter due to seasonality in international orders and state fiscal budget cycles.
• Financial Constraints: OCF break-even pushed to late 2027 due to the delayed contribution from CTNG and the time required for Ebola and Colipi ramps to fully offset costs.

Management Commentary and Tone:

• Tone was confident and execution-focused, emphasizing "return to growth" and strategic discipline despite regulatory setbacks.
• Management expressed strong conviction in the long-term value of the simplified portfolio, localized capabilities, and differentiated product pipeline.
• CEO Kerry Eglinton-Manner highlighted the strategic alignment of point-of-need diagnostics with the shifting global health landscape toward local sovereignty.
• CFO Ken McGrath emphasized the material reduction in operating spend and the durability of margin improvements.

Analyst Questions and Answers:

• CTNG Timeline: Management confirmed being in the FDA pre-sub process with multiple scenario plans; no specific resubmission date or cost update provided yet, though milestone payments may be deferred.
• Q4 Revenue Mix: Q4 guidance reflects a mix shift where SMS momentum in Q3 is expected to normalize while international diagnostic volumes are anticipated to recover; overall YoY growth remains strong.
• OCF Break-even Drivers: Confirmed the revised OCF timeline is driven by a combination of continued margin expansion, operating leverage, and the eventual ramp of revenue from Ebola, Colipi, and core business.
• Ebola Revenue Impact: No specific Q4 revenue contribution from Ebola disclosed; management noted "encouraged by initial orders" but expects the major catalyst for broader contracting to be the Bridge Access Study results.

Other Key Points:

• HPV Development: Continued investment in early development of HPV testing applications utilizing Colipi chemistry in partnership with global molecular diagnostic partners.
• Product Portfolio: The syndemic testing strategy (offering combined HIV, HCV, and syphilis solutions) is cited as a key differentiator for reaching high-risk populations.
• Investor Relations: Forward-looking statements were cautioned as typical, with actual results dependent on SEC filings and market conditions.
• Call Participants: Call featured CEO Kerry Eglinton-Manner and CFO Ken McGrath, with Q&A handled via operator with specific questions from analysts at Stevens and Craig Hallam.